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Abstract
Recent advances in tests for the sexually transmitted protozoan parasite Trichomonas vaginalis
have increased opportunities for diagnosis and treatment of this important sexually transmitted
infection. This review summarises currently available tests, highlighting their performance
characteristics, advantages and limitations. The recent development of molecular tests for the
detection of T vaginalis, including rapid antigen detection and nucleic acid amplification tests, has
significantly improved the quality of diagnostics for trichomoniasis, particularly in women. In
light of the expanded menu of testing options now available, improved recognition and better
control of trichomoniasis are in sight, which should enable the eventual reduction of adverse
reproductive consequences associated with T vaginalis infection.
INTRODUCTION
In 2008, 276.4 million incident cases of Trichomonas vaginalis infections were estimated by
WHO, which represent an increase of 11.2% compared with global estimates for 2005.1 The
incidence of trichomoniasis exceeds rates for gonorrhoea and chlamydial infection
combined; however, the development of sensitive and specific detection methods for this
sexually transmitted protozoan has lagged behind diagnostic testing for Neisseria
gonorrhoeae and Chlamydia trachomatis.
T vaginalis causes vaginitis and cervicitis in women and urethritis in men; however,
infections are often asymptomatic. Trichomoniasis is associated with adverse reproductive
sequelae including preterm birth and pelvic inflammatory disease in women and infertility in
women and men.23 Furthermore, T vaginalis infection increases sexual transmission of HIV,
and high rates of trichomoniasis have been reported among HIV-infected women.4–6 Likely
resulting from disrupted innate immune responses and increased inflammation in infected
genital mucosae, trichomoniasis doubles or triples the risk of acquiring HIV infection.2
Modelling studies indicate that T vaginalis may account for nearly 20% of HIV transmission
events from HIV-infected individuals when the prevalence of trichomoniasis is high.7
Trichomoniasis is not a reportable sexually transmitted infection (STI) in many countries,
including the USA, and comprehensive guidelines for testing are lacking or slowly
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emerging. In addition, wet mount microscopy, which is the diagnostic method traditionally
used to identify infection mainly in women, is insensitive. Thus, T vaginalis infection is
underappreciated by healthcare providers and patients alike. However, recent advances in
diagnostic tests to detect trichomonas offer hope for improved recognition and treatment,
which may lead to better control of this important STI. Herein we review the advantages and
limitations of the most commonly available contemporary methods for the diagnosis of T
vaginalis infection.
CLINICAL PRESENTATIONS OF TRICHOMONIASIS
The signs and symptoms of trichomoniasis are similar to those caused by other STIs and
bacterial vaginosis. Clinical presentations of trichomoniasis in women range from
asymptomatic to severe vaginitis characterised by diffuse, malodorous discharge or urethritis
characterised by dysuria. Cervicitis characterised by petechial haemorrhages on the
ectocervix (the so-called `strawberry cervix') may distinguish trichomoniasis from other
causes of cervicitis, but this is not frequently identified. The clinical presentation of
trichomoniasis in men exhibits a similar spectrum ranging from asymptomatic infection to
urethritis characterised by urethral discharge and dysuria. Asymptomatic T vaginalis
infections are common. Studies in sexually transmitted disease clinic populations suggest
that approximately 25% of women89 and 40%–75% of infected men with trichomoniasis are
asymtpomatic.810 Because the clinical manifestations of trichomoniasis are non-specific,
and infection is very often asymptomatic, accurate diagnosis of T vaginalis infection
requires appropriate laboratory testing.
LABORATORY TESTING FROM MICROSCOPY TO NUCLEIC ACID
AMPLIFICATION
Microscopy
Microscopic examination of a wet mount preparation of vaginal secretions mixed with
normal saline is the most common diagnostic evaluation for T vaginalis infection in women.
Direct observation of the pear-shaped trichomonads with their characteristic jerky or
tumbling motility is considered 100% specific for T vaginalis. Studies comparing wet mount
microscopy with highly sensitive molecular detection tests document the poor sensitivity of
microscopy, which ranges from 44% to 68%, even with experienced microscopists and
prompt examination of vaginal specimens.11–13w1w2 Delays as short as 10–30 min between
specimen collection and microscopic examination can dramatically reduce the sensitivity of
the test.14 In addition, suboptimal specimen storage or transportation conditions, especially
temperatures below 22°C, further reduce parasite motility and thus wet mount sensitivity.
Key features of microscopy and other available tests are summarised in table 1.
The microscopic detection of trichomonads is often reported as an incidental finding in
Papanicolaou (Pap) smears of cervical specimens. The conventional Pap smear technique is
considered unreliable for diagnosis of T vaginalis infection with poor sensitivity and
specificity, and confirmatory testing with a more sensitive and specific test is recommended
for asymptomatic women with trichomoniasis diagnosed by conventional Pap. However,
recently developed liquid-based Pap tests appear to be more accurate for microscopic
identification of T vaginalis. Reported sensitivities range from 60% to 96% and specificities
from 98% to 100%,1516 suggesting that treatment of trichomoniasis identified in liquid-
based Pap test pathology reports, without additional testing, may be justified.
Microscopic examination of vaginal wet mounts and liquid-based Pap specimens are widely
available and relatively inexpensive. Wet mount microscopy has the advantage of providing
immediate results as a point-of-care test; liquid-based Pap test results are typically available
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several days after specimen collection. Unfortunately, microscopic examination of male
urethral specimens or urine sediment is unreliable for detection of T vaginalis infection in
men due to the lower organism burden.22
Culture
Biological amplification of T vaginalis in liquid culture provides improved sensitivity over
direct microscopic observation. Culture techniques include the use of Diamond's modified
medium, available in glass tubes from commercial microbiological media suppliers, and the
InPouch TV test (Biomed Diagnostics, Oregon, USA). Specimens from women (vaginal
swabs) or men (urethral swabs or urine sediment) should be used to immediately inoculate
the culture medium less than 1 h after collection. Cultures are incubated at 37°C and
examined microscopically each day for up to 5 days until motile trichomonads are observed.
Cultures from women with trichomoniasis are usually positive within the first 3 days after
inoculation. However, cultures from men should be examined daily for 5 days or longer
before being considered negative, as extended incubation times are often required to permit
growth of detectable numbers of organisms from specimens from male specimens.22
InPouch TV is a self-contained culture pouch made of oxygen-resistant, optically clear
plastic that can be microscopically examined directly, eliminating the need to remove
material from the culture for daily examination. InPouch TV can be stored at room
temperature before use, and inoculated pouches can remain at room temperature up to 48 h
before incubation at 37°C (Biomed product insert). Diamond's medium must be stored at
4°C before use, warmed to room temperature before inoculation and cultures should be
incubated immediately at 37°C under anaerobic conditions.
Compared with highly sensitive nucleic acid amplification tests (NAATs) the sensitivity of
culture ranges from 44% to 75% for detection of T vaginalis in specimens from
women.1112w1w3 In men, the sensitivity of culture ranges from 40% to 56% for detection of
T vaginalis;22w4 urine from men is more sensitive than a urethral swab specimen for
culture.22 Based on visualisation of viable, motile trichomonads, culture is 100% specific for
detection of T vaginalis. Liquid culture media are relatively inexpensive, but the cost of
culture is increased by the requirement for daily examination by a trained microscopist, and
final results may take up to a week.
Rapid diagnostic tests
Traditional wet mount microscopy and culture require rapid specimen handling, processing
and transport conditions to preserve viable, motile organisms. In contrast, several recently
developed non-culture tests that detect T vaginalis antigens or nucleic acids allow for
extended time between specimen collection and testing and more flexible sample storage
temperatures. Commercially available antigen detection tests include the OSOM
Trichomonas Rapid Test (Sekisui Diagnostics, California, USA) and the Tv latex
agglutination test (Kalon Biological, Surrey, UK). OSOM is a US Food and Drug
Administration (FDA)-cleared point-of-care, immunochromatographic strip test that uses
specific antibodies to detect trichomonas protein antigens. When present, T vaginalis
antigens bind the antibodies resulting in the formation of a blue line on the test strip. Sample
processing and testing require no instrumentation, and results are available in 30 min or less.
The Kalon Tv latex agglutination test is not registered with the US FDA and does not bear a
Conformité Européenne (CE) mark for use as a diagnostic device in the European Union
(EU); it is a point-of-care test that uses latex beads coated with specific antibody to detect
trichomonas protein antigens. When present, T vaginalis antigens cause the beads to
agglutinate on a glass slide. Sample processing and testing require no instrumentation, and
results are available in 10 min or less.
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Affirm VPIII (Becton Dickinson, Maryland, USA) is a non-amplified nucleic acid probe
hybridisation test for detection of T vaginalis, Gardnerella vaginalis and Candida albicans.
Affirm VPIII is a US FDA-cleared test and bears the EU CE mark. Affirm uses specific
oligonucleotide probes to detect T vaginalis (also G vaginalis and C albicans) nucleic acids;
sample processing and testing require a heating block and a processor instrument. The test
can be done in approximately 1 h, but in practice, samples are usually batched, and the
moderate complexity Affirm test is not routinely used as a rapid test.23
The sensitivities of the non-culture, non-amplified tests described above are similar to
culture and consistently higher than wet mount microscopy. and range from 40% to 95%
depending on the specific test and the reference standard.91317–21 These tests are highly
specific for T vaginalis with clinical specificities ranging from 92% to 100%.91317–21
OSOM, Tv latex and Affirm are all intended for use with vaginal swabs from symptomatic
women or women with suspected exposure to trichomoniasis; none of these tests has been
evaluated for screening asymptomatic women or for diagnosis of trichomoniasis in men.
Nucleic acid amplification tests
As with other STIs, the advent of highly sensitive and specific NAATs has provided critical
new tools for diagnosis of infections with T vaginalis. NAATs include PCR, transcription-
mediated amplification (TMA) and other technical variations on a biochemical theme
characterised by the replication and amplification of millions of copies from specific
individual DNA or RNA target sequences. Thus, the analytical sensitivity of NAATs is
inherently greater than that of microscopy, culture, antigen detection or nucleic acid probe
assays, which detect existing organisms or their constituents. The high analytical specificity
of NAATs stems from the use of nucleotide primer and probe sequences that are unique to
the target organism. Standard procedures during the development of inhouse and
commercial NAATs for diagnosis of STIs include verification that the tests do not detect
pathogens and common microbial inhabitants of the urogenital tract other than the intended
target and that the presence of other organisms does not interfere with detection of the
target.
Several inhouse PCR assays have been described and validated in individual laboratories for
detection of T vaginalis in women and men.12w1w3–w7 The TMA-based APTIMA T
vaginalis assay (Hologic Gen-Probe Inc, California, USA) is the first commercial NAAT to
receive the EU CE mark and US FDA clearance for in vitro diagnostic use to detect T
vaginalis in women.24 APTIMA uses specific rRNA target capture, TMA and detection of
amplified products by a hybridisation protection assay and requires a high complexity
instrumentation system and trained laboratory personnel. Consequently, APTIMA is not a
point-of-care test, and costs are correspondingly higher than for many of the non-NAATs.
Specimens are typically obtained and placed in APTIMA transport medium at the site of
collection and sent to large laboratories using the automated TIGRIS DTS System, where
results for hundreds to thousands of specimens are reported daily. A manual DTS
instrumentation system is also available for smaller laboratories, and APTIMA assay
clearance for use with an automated PANTHER System for small to mid-sized laboratories
is forthcoming.
The increased sensitivity of NAATs compared with the non-amplified tests, combined with
convenient specimen processing that preserves nucleic acids but not viable organisms, has
several important advantages for diagnosis of trichomoniasis in both men and women. T
vaginalis NAAT sensitivities range from 76% to 100%,12132124w1–w7 making these tests
suitable for screening and testing asymptomatic female and male patients, in whom
trichomoniasis is typically characterised by relatively low organism burdens. A variety of
urogenital specimens can be used with NAATs, including non-invasive urine and minimally
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invasive self-collected vaginal swabs in addition to clinician-collected vaginal, urethral and
endocervical swabs; endocervical specimens collected for liquid-based Pap cytology can
also be used for NAATs. T vaginalis is considered to be primarily a vaginal pathogen, in
contrast to N gonorrhoeae and C trachomatis, which typically infect the endocervix.
However, all three organisms can be readily detected in either an endocervical or vaginal
specimens using highly sensitive NAATs.24
Because viable organisms are not required, specimen storage, processing and transport allow
for a wider range of temperatures and time intervals between specimen collection and
testing. Thus, NAATs can facilitate testing in diverse settings from clinical to non-clinical
venues and can be applied for screening in population-based epidemiological studies.
Specimens obtained for T vaginalis NAATs are appropriate and usually contain sufficient
quantity for detection of other STIs including N gonorrhoeae and C trachomatis. Thus,
combined testing for trichomoniasis, gonorrhoea and chlamydial infection is feasible from a
single urogenital specimen.w8
The potential of NAATs to detect non-viable organisms imposes limitations on their use as
tests of cure for trichomoniasis. Although NAATs may remain positive for several days,
these tests are generally negative 2 weeks after successful treatment for T vaginalis
infection.25 The failure to preserve viable organisms in specimens processed for NAATs
also limits the potential for antimicrobial susceptibility testing for T vaginalis and other
pathogens for which the molecular basis of resistance is not known. Thus, although NAATs
may eventually supplant less sensitive tests for diagnosis of T vaginalis infection, culture
will continue to be important in cases of persistent infection or suspected treatment failure
for which antimicrobial susceptibility testing of clinical isolates may be warranted.
SPECIMEN COLLECTION AND TESTING STRATEGIES FOR T VAGINALIS
DIAGNOSIS
The choice of specimen, diagnostic test and testing strategy for detection of T vaginalis will
naturally depend on the patient population, clinical setting, available laboratory facilities and
cost considerations. In clinical settings where there is a high prevalence of STIs and there
are resources to support molecular diagnostic laboratory testing, collection of vaginal or
endocervical samples from women and urethral swabs or urine from men for NAATs will
likely provide optimal diagnosis of T vaginalis infections. If universal screening is not
feasible among all sexually active men and women presenting for STI evaluation, targeted
testing should be considered for women presenting with vaginitis, cervicitis or urethritis;
men with urethritis; and sexual partners of persons diagnosed with trichomonal infection,
preferably with NAATs.
In settings where physical examinations for STI evaluation are limited (eg, community-
based health centres, school-based clinics, correctional facilities, outreach venues or home
screening), non-invasive urine or self-collected vaginal swabs may be preferable. Only non-
culture-based testing is feasible in such situations because viable organisms cannot survive
the inevitable delays in specimen transport to a laboratory facility. Urine specimens could be
collected in those settings from both men and women, but testing would require transport to
a qualified laboratory for NAATs. Point-of-care testing might be practical for self-collected
vaginal swabs in such situations. Currently available rapid tests are not designed for use by
the general public and generally require some operator training. However, home specimen
collection and testing using a rapid antigen detection test have been shown to be feasible,
and women who were provided detailed instructions for vaginal swab collection and testing
produced reliable results.w9
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Numerous websites have been developed to offer internet-based STI testing. Most offer self-
collection kits and testing options for gonorrhoea and chlamydial infection, and increasingly
for trichomoniasis. Although a recent survey showed that the accuracy of STI tests offered
through internet sites is highly variable, mailed-in specimens tested in well-qualified
laboratories provide accurate test results.w10 The public health website http://
www.iwantthekit.org offers T vaginalis testing from self-collected vaginal swabs from
women and urine or self-collected penile swabs from men in select areas of the USA.2627w11
In men, the sensitivity of NAATs from self-collected penile swabs is higher than urine for T
vaginalis detection.28w11
In settings where molecular testing is not available, diagnosis of T vaginalis infection
remains problematic because wet mount microscopy alone performs poorly for the diagnosis
of trichomoniasis in women. In those settings, testing algorithms in which vaginal
specimens from wet mount-negative women are tested using a rapid antigen detection test
and/or culture can substantially improve detection of T vaginalis.29w12 Wet mount
microscopy and current rapid antigen detection tests are not suitable for diagnosis of
trichomoniasis in men; inoculation of culture media with multiple specimens (eg, a
combination of urine sediment and a urethral swab) increases the sensitivity of culture for
detection of T vaginalis infection and should be considered.30
SUMMARY AND CONCLUSIONS
Once regarded as merely a nuisance in women, T vaginalis infection can cause various
clinical presentations in both men and women and is a risk factor for HIV transmission. In
response to increasing recognition by clinicians, researchers and policymakers of the
importance of this widespread STI, new molecular diagnostic tests with improved sensitivity
have been developed and validated by manufacturers and in clinical and research
laboratories throughout the world. With enhanced awareness, availability and application of
these modern diagnostic tests, better detection and treatment of trichomoniasis in women
and in their sexual partners can be achieved with eventual reduction of adverse reproductive
consequences associated with T vaginalis infection.
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▶ A variety of diagnostic tests are now available to detect Trichomonas
vaginalis infection in women; fewer options are available for use in men.
▶ Rapid point-of-care tests with improved sensitivity compared with wet mount
microscopy should facilitate testing and treatment of women in clinical and
non-clinical settings.
▶ T vaginalis nucleic acid amplification tests enable incorporation of testing for
this infection in settings where molecular diagnostics for Neisseria
gonorrhoeae and Chlamydia trachomatis are already in place.
▶ Molecular diagnostic tests perform well with self-collected specimens and
can be used in innovative screening and testing programmes including
internet recruitment.
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Table 1
Key features of commonly available diagnostic tests for Trichomonas vaginalis infection
Category Test Sensitivity range* (%) Specificity range* (%) Advantages Limitations References
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NAAT, nucleic acid amplification test; Pap, Papanicolaou; STI, sexually transmitted infection; TV, Trichomonas vaginalis.
*
Wide ranges for sensitivity and specificity result from the use of different reference standards in published studies.
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